Exscientia
drug effects to enable discovery as | Exscientia
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
30 of 33
Related slides by other companies
23andMe
Investor Day
January 2022
was identified as a promising anti cancer drug target with proprietary immune oncology i genetic signature | 23andMe
ATAI
Investor Presentation
October 2022
placebo inclusion in suggests agreement of agency with both placebo and dose controlled pivotal trials and the potential implications of functional in the former assumable acceptance by agency of psychological and elements of digital support as an integral part of the therapeutic approach for no requirement of factorial trials to tease out drug effect the effect of these supporting tools design of involving doses suggests that agency is comfortable with repeat dosing in the context of drug development if these trials are successful will pave the way for the other drugs in pipeline developed for especially phase study informs our generation compounds | ATAI
Other recent decks by Exscientia
See all presentations (14 decks)
Investor Presentation
March 2024
Results
March 2024
Investor Day
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights